戻る
X T L Biopharmaceuticals Ltd (XTLB) 収入
XTLB 株価推移チャート
XTLB 収入
X T L Biopharmaceuticals Ltd
$2.51
-4.56%
$-0.12
終値： Mar 27, 16:00:00 GMT-4
$2.51
0%
$0
アフターマーケット：Mar 27, 20:00:00 GMT-4
Earnings FAQ
XTLBの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
X T L Biopharmaceuticals Ltd XTLBの前四半期の収益はどうでしたか？
X T L Biopharmaceuticals Ltdの収益見積もりはいくらですか？
X T L Biopharmaceuticals Ltdの収益品質スコアはどれくらいですか？
X T L Biopharmaceuticals Ltdはいつ収益を報告しますか？
X T L Biopharmaceuticals Ltdの予想収益はいくらですか？
X T L Biopharmaceuticals Ltdは収益予想を上回りましたか？
主要データ
前終値
$2.63
始値
$2.55
当日レンジ
$2.45 - $2.66
52週レンジ
$0.53 - $2.64
取引高
6.5K
平均取引高
736.3K
配当利回り
--
1株当たり利益(TTM)
-0.90
時価総額
$23.7M
XTL Biopharmaceuticals Ltd.とは何ですか？
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.